| Literature DB >> 36186733 |
Juan Luo1, Yijie Wang2, Xiangqian Dong1, Wen Wang1, Yanju Mu1, Yang Sun1, Fengrui Zhang1, Yinglei Miao1.
Abstract
The incidence rate of ulcerative colitis (UC) is increasing annually, and glucocorticoid (GC) resistance (GCR) is a common cause of UC-induced remission failure. Our previous studies have shown that the expression of miR-642a-5p is downregulated in UC with GCR, suggesting that miR-642a-5p may be related to the GC response. Therefore, we investigated the mechanism by which miR-642a-5p regulates the GC response in THP-1 cells. We found that after treatment with miR-642a-5p mimics and DEX, the expression levels of glucocorticoid receptor (GR) in the nucleus and NF-κB p65 and p50 in the cytoplasm were increased (P < 0.05). miR-642a-5p mimics transfected into THP-1 cells could synergize with dexamethasone (DEX) to reduce lipopolysaccharide (LPS)-induced inflammatory factor levels such as TNF-α, IL-1β, IL-6 and IL-12 (P < 0.05). Bioinformatics analysis and luciferase reporter assays confirmed that TLR4 is a target gene of miR-642a-5p. miR-642a-5p mimic pretreatment enhanced the inhibitory effect of DEX on TLR4 induced by LPS and inhibited the expression of TLR4 on the cell surface (P < 0.05). Additionally, miR-642a-5p further prevented the nuclear import of NF-κB P65 and inhibited the phosphorylation of ERK, p38 and JNK. These results suggest that miR-642a-5p can inhibit the inflammation by suppressing the TLR4 signalling pathway in THP-1 cells. It also highlights the TLR4 signalling pathway as a potential therapeutic target in anti-inflammation.Entities:
Keywords: GCR, Glucocorticoid resistance; Glucocorticoid resistance; Glucocorticoid sensitivity; TLR4, Toll-like receptor 4; Toll-like receptor 4; Ulcerative colitis; miR-642a-5p
Year: 2022 PMID: 36186733 PMCID: PMC9519937 DOI: 10.1016/j.bbrep.2022.101356
Source DB: PubMed Journal: Biochem Biophys Rep ISSN: 2405-5808
Fig. 1miR-642a-5p had no effect on the proliferation or death of THP-1 cells.
Fig. 2Transfected miR-642a-5p mimics synergized with DEX to promote GR translocation into the nucleus in cells.
A–B: Immunofluorescence detection of the expression of GR in or out of the nucleus. C–E: Western blot detection of the expression of GR translocation into the nucleus. F–I: ELISA detection of the expression levels of the inflammatory factors TNFα, IL-1β, IL-6, and IL-12 in cells transfected with miR-642a-5p mimics. n = 3. * indicates P < 0.05.
Fig. 3Validation that TLR4 is the target gene of miR-642a-5p. A: Bioinformatics analysis for the TLR4 and miR-642a-5p. B: Luciferase experiments of the wt-TLR4 and miR-642a-5p. C: qPCR detection of the level of the TLR4 mRNA in miR-642a-5p mimic-transfected cells. D: Western Blot detection of the expression of the TLR4 protein in miR-642a-5p mimic-transfected cells. E: qPCR detection of the level of the TLR4 mRNA in miR-642a-5p mimic-transfected cells induced by LPS or DEX. F: Flow cytometry detection of the protein expression of TLR4 on the surface of the miR-642a-5p mimic-transfected cells induced by LPS or DEX. n = 3. * indicates P < 0.05.
Fig. 4miR-642a-5p cooperated with DEX to prevent the nuclear entry of NF-κB P65 and P50. A: Western blot analysis of the nuclear entry of NF-κB P65 and P50. B: Immunofluorescence staining to detect the nuclear entry of NF-κB P65. C–D: Western blotting was used to detect the expression and phosphorylation of TLR4, MyD88, TAK1, ERK, p38 and JNK. n = 3. *, p < 0.05 vs. no-treatment; #, p < 0.05 vs. LPS treatment; &, p < 0.05 vs. LPS + Dex treatment.